- Home
- TDTH vs IRD Comparison
TDTH vs IRD Comparison
Compare TDTH & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- IRD
- Stock Information
- Founded
- TDTH 2014
- IRD 2018
- Country
- TDTH Singapore
- IRD United States
- Employees
- TDTH N/A
- IRD N/A
- Industry
- TDTH
- IRD
- Sector
- TDTH
- IRD
- Exchange
- TDTH NYSE
- IRD NYSE
- Market Cap
- TDTH 20.0M
- IRD 59.1M
- IPO Year
- TDTH 2024
- IRD N/A
- Fundamental
- Price
- TDTH $0.73
- IRD $1.10
- Analyst Decision
- TDTH
- IRD Strong Buy
- Analyst Count
- TDTH 0
- IRD 3
- Target Price
- TDTH N/A
- IRD $6.33
- AVG Volume (30 Days)
- TDTH 10.5M
- IRD 744.9K
- Earning Date
- TDTH 07-22-2025
- IRD 08-15-2025
- Dividend Yield
- TDTH N/A
- IRD N/A
- EPS Growth
- TDTH N/A
- IRD N/A
- EPS
- TDTH N/A
- IRD N/A
- Revenue
- TDTH $465,435.00
- IRD $13,651,000.00
- Revenue This Year
- TDTH N/A
- IRD $51.41
- Revenue Next Year
- TDTH N/A
- IRD $68.84
- P/E Ratio
- TDTH N/A
- IRD N/A
- Revenue Growth
- TDTH N/A
- IRD N/A
- 52 Week Low
- TDTH $0.17
- IRD $0.65
- 52 Week High
- TDTH $4.74
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- IRD N/A
- Support Level
- TDTH N/A
- IRD N/A
- Resistance Level
- TDTH N/A
- IRD N/A
- Average True Range (ATR)
- TDTH 0.00
- IRD 0.00
- MACD
- TDTH 0.00
- IRD 0.00
- Stochastic Oscillator
- TDTH 0.00
- IRD 0.00
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings Ltd is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore. Its revenue is derived from business consulting service, IT customization and selling event tickets.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.